C9166 Secukinumab IV Injection Reimbursement

Headline: New HCPCS Level II code C9166 standardizes reporting for IV secukinumab doses

Lead: HCPCS Level II code C9166 denotes an intravenous injection of secukinumab, reported per 1 mg, providing a standardized vehicle for billing and policy tracking of IV-administered secukinumab at scale.

What it represents and national importance: The code specifically captures intravenous dosing of the interleukin-17A inhibitor secukinumab on a per-milligram basis. As biologic therapies expand across immunology and dermatology indications, a distinct HCPCS Level II code for IV secukinumab supports consistent billing, utilization monitoring, and payment determinations for infusion-delivered biologics nationwide.

Key payers covered: Analysis addresses major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

What readers will learn: The publication outlines clinical context for IV secukinumab administration, common sites of service, and payer coverage considerations. It summarizes where to expect billing with HCPCS Level II code C9166, highlights typical service settings (outpatient infusion centers and hospital outpatient departments), and notes the existence of common modifiers used in practice. The report also flags that specific payer policies, coverage criteria, and reimbursement rates vary by plan and are not provided here.

Additional notes: Associated taxonomies, ICD-10 diagnosis pairings, related codes, and precise service-line mapping are not available in the input and therefore omitted.

Billing Code Overview

HCPCS Level II code C9166 describes an intravenous injection of secukinumab, billed per 1 mg. The service type is intravenous biologic medication administration. The typical site of service for this administration is an outpatient infusion center or hospital outpatient department, where IV biologic therapies are commonly delivered.

Data not available in the input.

Clinical Context

A 52-year-old patient with severe plaque psoriasis refractory to subcutaneous biologic therapy is admitted to an infusion center for an initial loading dose of intravenous secukinumab. The infusion is ordered as C9166 (injection, secukinumab, intravenous, 1 mg) dosed per weight and protocol. The clinical workflow includes verification of patient identity and consent, review of prior biologic therapies and infection screening (including TB and hepatitis), baseline vitals and labs, preparation of the IV dose by pharmacy, IV access placement by an infusion nurse, administration under monitored conditions with periodic vital signs, documentation of lot number and dose, observation for infusion reactions for at least 30–60 minutes post-dose, and discharge instructions documenting return precautions and follow-up dermatology or rheumatology appointment. Typical sites of service include hospital outpatient infusion centers, physician office infusion suites, and ambulatory infusion centers. Common payors for authorization and claims processing include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased Procedural Services	Use when work, time, or intensity of IV preparation/administration is substantially greater than usual (document justification).

Taxonomy Code	Specialty	Notes
`208000000X`	Dermatology	Dermatologists commonly order secukinumab for moderate to severe plaque psoriasis.
`207R00000X`	Rheumatology	Rheumatologists prescribe secukinumab for psoriatic arthritis and related indications.
`163W00000X`	Allergy & Immunology	Allergists/immunologists manage biologic therapy for immune-mediated skin and systemic diseases.
`164W00000X`	Internal Medicine (Infusion Medicine)	Hospitalists and infusion specialists oversee IV biologic administration and monitoring.
`363L00000X`	Nursing (Infusion Nurse)	Infusion nurses perform IV access, administration, and patient monitoring.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L40.0`	Psoriasis vulgaris	Primary indication for secukinumab when plaque psoriasis is moderate to severe and systemic therapy is indicated.
`L40.5`	Arthropathic psoriasis	Reflects psoriatic arthritis where secukinumab is indicated to control both skin and joint disease.
`M07.0`	Distal interphalangeal psoriatic arthropathy	Specific psoriatic arthritis manifestation treated with biologic therapy.
`M07.3`	Psoriatic spondylitis	Axial involvement of psoriatic disease where IL-17 inhibitors may be used.
`M06.9`	Inflammatory polyarthritis, unspecified	Used when seronegative inflammatory arthritis is present and secukinumab is considered.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Used for baseline or monitoring labs before or during the infusion episode.
`36000`	Introduction of needle or intracatheter, vein	Used if peripheral IV access is placed for the infusion.
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used to report the infusion administration time for the IV dose when an infusion service is billed.
`96366`	Each additional hour (List separately in addition to code for primary infusion)	Used for extended infusion time beyond the initial hour when warranted by protocol.
`96374`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); push, single or initial substance/drug	Used if portions of the medication are administered as IV push rather than infusion per protocol.

OpenPayer

Summary & Overview

HCPCS C9166: Secukinumab Intravenous Injection, 1 mg